Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Notes have priced
Quarterly results
|
|
Clovis Oncology, Inc. (CLVS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/13/2019 |
GN
| New Research Coverage Highlights Amicus Therapeutics, Clovis Oncology, YRC Worldwide, FORTERRA INC, Shenandoah Telecommunications, and Basic Energy Services — Consolidated Revenues, Company Growth, and Expectations for 2019 |
| 08/27/2018 |
GN
| Recent Analysis Shows KalVista Pharmaceuticals, IZEA, Sonic Automotive, Catabasis Pharmaceuticals, ANI Pharmaceuticals, and Clovis Oncology Market Influences — Renewed Outlook, Key Drivers of Growth |
| 06/03/2018 |
GN
| Clovis Oncology and Immunomedics Announce Planned Clinical Collaboration to Study Combination Therapies in Metastatic Triple-Negative Breast and Urothelial Cancers |
| 05/09/2018 |
GN
| Consolidated Research: 2018 Summary Expectations for Catalent, MGIC Investment, United Rentals, Clovis Oncology, Pure Storage, and Chipotle Mexican Grill — Fundamental Analysis, Key Performance Indications |
| 03/07/2018 |
GN
| Research Report Identifies Tapestry, Burlington Stores, GoDaddy, Clovis Oncology, Darden Restaurants, and General Cable with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement |
| 11/14/2017 |
GN
| CORRECTING and REPLACING – Recent Analysis Shows Pure Storage, Catalent, Boyd Gaming, Halozyme Therapeutics, Clovis Oncology, and General Cable Market Influences – Renewed Outlook, Key Drivers of Growth |
| 11/13/2017 |
GN
| Recent Analysis Shows Pure Storage, Catalent, Boyd Gaming, Halozyme Therapeutics, Clovis Oncology, and General Cable Market Influences – Renewed Outlook, Key Drivers of Growth |
| 06/14/2017 |
GN
| Sienna Biopharmaceuticals Appoints Erle Mast, Former CFO and Co-Founder of Clovis Oncology, to Board of Directors |
| 04/27/2017 |
GN
| Myriad Genetics and Clovis Oncology Sign Agreement for Use of FDA-Approved BRACAnalysis CDx® Test to Identify Patients with Germline BRCA Mutations for Rubraca® (rucaparib) Treatment |
| 04/27/2017 |
GN
| Myriad Genetics and Clovis Oncology Sign Agreement for Use of FDA-Approved BRACAnalysis CDx® Test to Identify Patients with Germline BRCA Mutations for Rubraca® (rucaparib) Treatment |
| 02/14/2017 |
GN
| Update in Lawsuit for Investors in shares of Clovis Oncology Inc (NASDAQ:CLVS) announced by Shareholders Foundation |
|
|